Ultragenyx to Participate in Investor Conferences in December
Rhea-AI Summary
Ultragenyx (NASDAQ: RARE) announced that Chief Medical Officer Eric Crombez, M.D. will participate in fireside chats at two investor conferences in early December 2025: Citi’s 2025 Global Healthcare Conference in Miami on December 2, 2025 and the 8th Annual Evercore ISI Healthcare Conference in Coral Gables on December 3, 2025.
The company said live and archived webcasts of both presentations will be available on its investor website at https://ir.ultragenyx.com/events-presentations. Contact for investors is Joshua Higa at ir@ultragenyx.com.
Positive
- None.
Negative
- None.
NOVATO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in two upcoming investor conferences.
Citi’s 2025 Global Healthcare Conference (Miami, FL)
- Tuesday, December 2, 2025, Eric Crombez, M.D., Chief Medical Officer will participate in a fireside chat.
8th Annual Evercore ISI Healthcare Conference (Coral Gables, FL)
- Wednesday, December 3, 2025, Eric Crombez will participate in a fireside chat.
The live and archived webcast of the fireside chats will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
FAQ
When will Ultragenyx (RARE) present at Citi’s 2025 Global Healthcare Conference?
When will Ultragenyx (RARE) appear at the Evercore ISI Healthcare Conference?
How can investors watch Ultragenyx (RARE) conference presentations live or on demand?
Who from Ultragenyx (RARE) is scheduled to speak at the December 2025 investor conferences?
What investor contact should I use for Ultragenyx (RARE) conference inquiries?
Which dates should shareholders note for Ultragenyx (RARE) December 2025 events?
